Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy

BACKGROUND: Lenvatinib is a novel tyrosine kinase inhibitor that exhibits an antitumor effect on hepatocellular carcinoma (HCC). An established strategy that involves surgery and usage of lenvatinib for advanced HCC remains elusive. CASE PRESENTATION: A 58-year-old male patient with advanced HCC and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohya, Yuki, Hayashida, Shintaro, Tsuji, Akira, Kuramoto, Kunitaka, Shibata, Hidekatsu, Setoyama, Hiroko, Hayashi, Hironori, Kuriwaki, Kazumi, Sasaki, Masato, Iizaka, Masayoshi, Nakahara, Osamu, Inomata, Yukihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728870/
https://www.ncbi.nlm.nih.gov/pubmed/33301055
http://dx.doi.org/10.1186/s40792-020-01078-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728870/
https://www.ncbi.nlm.nih.gov/pubmed/33301055
http://dx.doi.org/10.1186/s40792-020-01078-3

Ejemplares similares